TN2013000172A1 - Formulations comprising polyethylene glycol - Google Patents

Formulations comprising polyethylene glycol

Info

Publication number
TN2013000172A1
TN2013000172A1 TNP2013000172A TN2013000172A TN2013000172A1 TN 2013000172 A1 TN2013000172 A1 TN 2013000172A1 TN P2013000172 A TNP2013000172 A TN P2013000172A TN 2013000172 A TN2013000172 A TN 2013000172A TN 2013000172 A1 TN2013000172 A1 TN 2013000172A1
Authority
TN
Tunisia
Prior art keywords
polyethylene glycol
solid
formulations
formulation
suckable
Prior art date
Application number
TNP2013000172A
Other languages
French (fr)
Inventor
Peter Stein
Ian Cox
Leighton Jones
Samuel Smith
Jorg Plessl
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2011/001560 external-priority patent/WO2012059724A1/en
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of TN2013000172A1 publication Critical patent/TN2013000172A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipation in healthy subjects. In some embodiments, the solid formulation is chewable or suckable.
TNP2013000172A 2011-11-04 2013-04-22 Formulations comprising polyethylene glycol TN2013000172A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2011/001560 WO2012059724A1 (en) 2010-11-04 2011-11-04 Formulations comprising polyethylene glycol

Publications (1)

Publication Number Publication Date
TN2013000172A1 true TN2013000172A1 (en) 2014-11-10

Family

ID=54360609

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000172A TN2013000172A1 (en) 2011-11-04 2013-04-22 Formulations comprising polyethylene glycol

Country Status (1)

Country Link
TN (1) TN2013000172A1 (en)

Similar Documents

Publication Publication Date Title
MY164204A (en) Formulations comprising polyethylene glycol
HN2011003011A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
CA2865972C (en) Inhalable dry powders
MX2013001677A (en) Stable formulations of linaclotide.
AR081681A1 (en) METHODS AND COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF b-GALACTOCEREBROSIDASA
MY161595A (en) Oral care compositions
BR112013026363A2 (en) nanosuspensions of freeze-dried drug
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
HN2006009000A (en) PHARMACEUTICAL FORMS WITH IMPROVED PHARMACOCINETIC PROPERTIES
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012019997A2 (en) oral care compositions
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012064304A3 (en) Combinations comprising montelukast
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
TR201902755T4 (en) LYOPHILIZED TRIPEPTIDE FORMULATIONS WITH STORAGE STABILITY.
IN2014MN01382A (en)
TN2013000172A1 (en) Formulations comprising polyethylene glycol
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms
UA97076C2 (en) Anti-inflammatory ointment based on sulfanilamide
MX357329B (en) Raw extract of a sechium edule hybrid, method for extracting same and use thereof for formulations having an antineoplastic effect.
UA59396U (en) Use of compositions of non-steroid anti-inflammatory drugs and caffeine as antiexudative agents